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Prevalence, clinical correlates, and use of glucose-lowering drugs were comprehensively evaluated among 863 nursing home older
patients with diabetes (mean age 82.9 ± 2.1 years): functional dependence and cognitive impairment were present in 84.1% and
68% of patients, respectively, and 66.3% of patients had 2–4 comorbidities. HbA1c values < 7.0% were documented in 54.9%
of diabetic; significantly lower HbA1c levels were observed in demented patients than in nondemented subjects. Documented
hypoglycemic episodes were reported for 57 patients (6.6%), without significant association with age, functional dependence,
cognitive impairment, or HbA1c levels. About one-fifth of older long-term facilities residents have diabetes, with concomitant
poor health conditions and high prevalence of cognitive impairment and functional dependence. Roughly three-fourths of these
older and frail diabetic patients have HbA1c values lower than optimal, suggesting a potential for hypoglycemic harm especially
among patients with severe cognitive impairment.
1. Introduction
There are few evidences about type 2 diabetesmellitus (T2DM)
in frail elderly subjects and, specifically, in older patients
living in long-term care residences [1–3]. These patients have
usually reduced life expectancy, poor general health, and at
least some degree of functional dependence and/or cogni-
tive impairment. They represent those frail and vulnerable
patients affected by T2DM for whom recent international
guidelines specifically recommended less stringent glycemic
targets and prioritized well-being and quality of life [4–6].
Duration of diabetes and advancing age independently
predict morbidity and mortality rates in elderly subjects.
Recent observations, demonstrating that cardiovascular
complications and hypoglycemia are common among older
diabetic patients, support the reorientation of care of older
patients with T2DM away from intensive glycemic control as
the core focus of management [7]. Target goal for glycated
hemoglobin (HbA1c) in older adults generally should be 7.5%
to 8%. Although HbA1c between 7% and 7.5% may be appro-
priate if it can be safely achieved in healthy older adults with
few comorbidities and good functional status, higher HbA1c
targets (8%-9%) are appropriate for older adults withmultiple
comorbidities, poor health, and limited life expectancy [4–6].
Moreover there is potential harm in lowering HbA1c to less
than 6.5% in older adults with type 2 DM [8].
Despite these recommendations for older vulnerable dia-
betic patients, there is little evidence on prevalence, clinical
correlates, and treatment of T2DM in elderly patients living
in long-term care facilities. In the present study we aimed to
comprehensively evaluate prevalence, clinical correlates, and
use of glucose-lowering drugs among nursing home older
patients with diabetes.
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2. Materials and Methods
In this prospective observational study, patients living in 83
long-term care facilities in Piedmont, Northern Italy, were
evaluated during the period of March–August 2013; all
patients aged >65 and affected by diabetes were enrolled,
without exclusion criteria.
Signed informed consent from patients or carer was
obtained for all participants and the study was conducted
according to the Recommendations Guiding Physicians in
Biomedical Research Involving Human Subjects [9].
For all the patients the following information was
recorded: identification, age, gender, and date of admission.
Relevant conditions (as dementia, immobilization, and pres-
sure sores) were also recorded. A thorough medical chart
review was performed in order to ascertain, as far as possible,
type and age of onset of diabetes, current hypoglycemic
therapy, previous hypoglycemic episodes, and last available
blood chemistries including serum glucose and glycated
hemoglobin (HbA1c) levels and pre- and postprandial glu-
cose levels. Total daily drug burden was also recorded.
Body mass index (BMI, according to the formula weight
(kg)/height (m2)) was calculated and categorized in 4 classes
(underweight: BMI < 18; normal weight: BMI 18–24.9; over-
weight: BMI 25–29.9; obesity: BMI ≥ 30). Standardized scales
were used for the evaluation of functional autonomy and
cognitive status. Functional status was evaluated using the
Activities of Daily Living (ADL) scale [10] that measures
six functions relating to activities necessary for self-care, in
each of which the patient can be described as autonomous
or dependent; a score equal to or higher than 2 identifies
functional dependence. Cognitive status was evaluated using
theMini-Mental State Examination [11], a questionnaire eval-
uating several cognitive domains; score between 19 and 24/30
identifies mild cognitive impairment, while score between 10
and 18/30 and score below 10/30 identifymoderate and severe
cognitive impairment, respectively.
The data, collected on preprinted standardized protocols
and subsequently transferred to MS Excel (Microsoft Inc.),
were analyzed using SPSS/PC+. A preliminary explorative
analysis was performed on continuous variables to assess
normal distribution (skewness and kurtosis). The frequency
of dichotomous and categorical variables was calculated,
as well as the average and the standard deviation (SD) of
continuous variables. Variables with Gaussian distribution
were analyzed using Student’s 𝑡-test and analysis of variance;
variables without Gaussian distribution were analyzed using
Pearson’s Chi-square test. Dichotomous variables were ana-
lyzed using Chi-square test. The ANOVA test was used to
evaluate differences between groups.
3. Results
Among 5076 residents in 83 long-term facilities, 863 patients
with diabetes (17%, mean age 82.9 ± 2.1 years) were identified
(Table 1), with female patients being significantly older than
male patients (mean age 83.9 ± 1.9 versus 80.7 ± 2.2 years,
𝑃 < 0.05). Among patients affected by diabetes there was a
significantly greater prevalence of women than of men (582
Table 1: Characteristics of diabetic patients living in long-term
facilities.
Age (years)
Total 82.9 ± 2.1
Male 80.7 ± 2.2
Female 83.9 ± 1.9
Females 582 (67.4%)
BMI
≤18 46 (5.3%)
18–24.9 382 (44.3%)
25–29.9 206 (23.9%)
≥30 98 (11.4%)
N.D. 131 (15.1%)
Preprandial serum glucose
≤70mg/dL 47 (5.5%)
71–126mg/dL 398 (46.1%)
127–180mg/dL 224 (25.9%)
≥181mg/dL 153 (17.7%)
N.D. 41 (4.8%)
HbA1c
<7% 354 (54.9%)
7–8.5% 131 (20.4%)
>8.5% 159 (24.7%)
Functional dependence
Partial (ADL = 1) 435 (50.4%)
Total (ADL ≥ 2) 291 (33.7%)
Moderate-severe cognitive impairment
(MMSE ≤ 18) 616 (71.4%)
Comorbidities
0 7 (0.8%)
1-2 261 (30.3%)
3-4 388 (44.9%)
≥5 207 (24.0%)
women versus 281 men, 67.4% and 32.6% of diabetic patients,
resp.) and this difference was statistically significant among
patients aged 80 or more (𝑃 = 0.000). More than 97% of
patients were ascertained to be affected by T2DM. Clinical
documentation about age of onset of DMwas retrievable only
in 25.3%of patients:meanduration of T2DM in these patients
was 12.9 ± 2.1 years at the moment of observation.
It was possible to measure height and weight in 732
patients: roughly half of older diabetic patients were normal
or underweight (44.3% and 5.3%, resp.), while a condition
of overweight and obesity was documented in 23.9% and
11.4% of patients, respectively. Functional autonomy was
documented in 15.9% of older diabetic patients, whereas
partial or complete functional dependence was present in
50.4% and 33.7% of patients, respectively; 9.2% of patients
were bedridden. Cognitive impairment was documented in
68% of diabetic patients, which was graded mild, moderate,
and severe in 28.6%, 40.1%, and 31.3% of them, respectively.
Coexistence of some degree of functional dependence and
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Figure 1: Distribution of cognitive impairment according to func-
tional class among older diabetic patients.
cognitive impairment was documented in 95.9% of patients
(Figure 1). At least one comorbidity was observed in 99.2%
of patients, with 66.3% of patients having 2–4 severe comor-
bidities. Hypertension (61.9%), dementia (36.8%), history
of cardio- (22.8%) and cerebrovascular (21.3%) events, and
bone fractures (13.4%) were the most common comorbidities
observed.
At the moment of data collection, 14.4% of diabetic
patients were not receiving hypoglycemic therapy, 41.3%were
treated with oral hypoglycemic drugs, 35.3% were receiving
insulin therapy, and 9.0% received combination therapy
with oral hypoglycemic drugs and insulin. Among patients
treated with oral hypoglycemic drugs, metformin was used
by 61.5%, sulphonylureas by 33%, repaglinide by 9.3%, and
a combination of metformin and glibenclamide by 4.8%; the
remaining patients were treatedwithmetformin and pioglita-
zone (0.8%), acarbose (0.8%), and metformin and DPP4
inhibitors (0.6%).
Among patients treated with insulin, 239 used rapid-
acting insulin (25.4% human and 74.6% analogue), 58 were
treated with intermediate-acting insulin, and 219 used long-
acting (glargine or detemir) insulin (90.4% and 9.6%, resp.).
Among patients treated with insulin therapy, 45.4% received
4 doses a day and 33.1% received 3 doses daily.
At least one value of glycated hemoglobin (HbA1c) was
available in 74.6% of patients: 54.9% of patients had HbA1c
values < 7.0%, 20.4% had HbA1c values between 7.0% and
8.5%, and 24.1% of patients had HbA1c values above 8.5%.
In the total sample of older diabetic patients, no significant
association was observed between classes of HbA1c level
(<7.0%, 7.0–8.5%, and >8.5%) and either functional depen-
dence or presence and severity of cognitive impairment, as
well as mean HbA1c values, did not significantly differ in
patientswith orwithout functional dependence and cognitive
impairment. Significantly lower HbA1c levels were observed
in demented patients than in nondemented subjects (6.92 ±
1.28% versus 7.23 ± 1.67%, 𝑃 = 0.013).
Preprandial glycemic values (available for 95.2% of
patients) below 126mg/dL were documented in 51.6% of
patients; 26% of patients had values between 126 and
180mg/dL and 17.7% had values above 180mg/dL. Post-
prandial glycemic values under 180mg/dL were observed
in 37.2% of patients, 18.1% of patients had values between
181 and 250mg/dL, and 8.1% of patients had values above
250mg/dL. For 36.6% of patients there were no data available
for postprandial glycemic values.
Documented hypoglycemic episodes were reported in
medical charts for 57 (6.6%) patients. At the moment of
data collection, 30 of these patients (52.6%) were treated
with insulin, 22 (38.5%) received oral hypoglycemic agents (9
receivedmetformin and glibenclamide, 2 receivedmetformin
and other sulphonylureas, 5 received metformin, 5 received
sulphonylureas, and 1 received metformin and repaglinide),
and 3 (5.2%) were treated with insulin and oral hypoglycemic
agents (2 with acarbose and 1 with glibenclamide); 2 of these
patients (3.5%) were not receiving drugs at the moment of
data collection.
Among patients with reported previous hypoglycemic
episodes 11 (19.3%) were bedridden and 19 (33.3%) were
affected by severe cognitive impairment. At the moment of
data collection, previous hypoglycemic episodes were not
associated with age, functional dependence, or cognitive
impairment, although a trend to a greater prevalence of
hypoglycemia among demented patients was observed.Mean
HbA1c levels were not significantly lower in patients with pre-
vious reported hypoglycemia than in other diabetic patients
(6.83 ± 1.18 versus 7.143 ± 1.37, 𝑃 = 0.08).
Single therapy with metformin was significantly more
prevalent among patients without reported hypoglycemic
episodes (𝑃 = 0.033). We did not observe significant asso-
ciation between use of sulphonylureas and hypoglycemic
episodes, but therapy with metformin and glibenclamide was
significantly more prevalent among patients with reported
previous hypoglycemic episodes (𝑃 = 0.004). Patients receiv-
ing insulin therapy were significantly more prevalent among
those with previous reported hypoglycemia (𝑃 = 0.009).
4. Discussion
We aimed to investigate prevalence, clinical correlates, and
use of glucose-lowering drugs among older patients with
T2DM living in long-term facilities in Piedmont, Northern
Italy. Our study demonstrated that T2DM is a common clini-
cal problem among these patients, affecting roughly less than
one-fifth of residents, with a greater prevalence of the disease
in women than in men. Extremely poor health conditions
were documented in these patients. Less than one-fifth of
them were functionally independent and roughly two-thirds
of them had some degree of cognitive impairment, with con-
comitant functional dependence and cognitive impairment
in more than 95% of patients. Two-thirds of patients had 2–4
severe comorbidities,mainly hypertension, dementia, cardio-
and cerebrovascular disease, and bone fractures. Finally, we
documented a high prevalence of low HbA1c values and a
remarkable incidence of documented hypoglycemic episodes
among these cognitively and functionally impaired older
residents.
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There are very few studies which investigated this item
in similar populations. The prevalence of T2DM observed in
our sample was in accordance with that observed in a French
study, which reported a prevalence of T2DM of 17.1% among
6275 older long-term facility residents aged 86 years [12].
Because mean duration of T2DM in the patients enrolled in
our study was around 12 years, it is reasonable to suppose that
diabetes onset inmost of the patients occurred probably at an
older age.
Despite current recommendations on hypoglycemic
treatment and HbA1c targets for older, frail, and vulnerable
patients [4–6] we found that more than half of long-term
facility older residents had HbA1c values below 7%, and 75%
of themhad levels below 8.5%.These findings demonstrate an
undesired and potentially harmful aggressive hypoglycemic
therapeutic approach in these frail and vulnerable patients.
There are very few evidences about overall health benefit
of hypoglycemic therapy among these frail patients, who
are more vulnerable to and at higher risk of incident
hypoglycemic episodes [8]. Therefore, recent international
guidelines support the reorientation of care of older patients
with T2DM away from intensive glycemic control as the core
focus of management [7], and HbA1c targets around 8%-
9% are deemed appropriate for older adults with multiple
comorbidities, poor health, and limited life expectancy [4–
6]. Moreover, HbA1c levels were significantly lower among
demented patients, who are more prone to the negative
consequences of hypoglycemia. There is a burden of evi-
dence linking hypoglycemia and cognitive decline: cogni-
tively impaired and demented patients are more prone and
vulnerable to hypoglycemia, which itself represents a major
risk factor for further cognitive decline [13–18]. Unawareness
of hypoglycemia and subtle or atypical clinical presentation
make extremely difficult an early diagnosis of hypoglycemia
in demented, frail patients, leading to the potential for major
harm in these patients.
Hypoglycemic episodes were reported in medical charts
in 6.6% of patients, probably underestimating the true
prevalence of this feared complication. Among patients
with reported hypoglycemic events, roughly one-fifth of
them were bedridden and one-third had severe cognitive
impairment. At the moment of data collection HbA1c values
below 7.5% were yet more frequent in patients with previ-
ous hypoglycemic episodes than in patients without prior
hypoglycemic episodes (75.4% versus 45.1%, 𝑃 = 0.03).
Combination therapywithmetformin and glibenclamide and
insulin therapy were both significantly more frequent among
patients with previous hypoglycemic episodes, whereas single
therapy with metformin was more prevalent among T2DM
patients without previous hypoglycemic episodes. These
findings are in keeping with and reinforce current Beers
recommendations about potentially inappropriate medica-
tion use in the elderly: metformin is considered the safest
oral glucose-lowering approach in diabetic patients without
specific contraindications, whereas rapid-acting insulins are
considered the drugs with the highest potential for harmful
hypoglycemic events [19]. However, because of the cross-
sectional retrospective medical charts study, these findings
should be carefully considered because we were able to
document current glucose-lowering drug therapy at the
moment of collection of data but we could not ascertain
frommedical charts which therapies were administered at the
moment of hypoglycemic crisis.
Some limitations of the present study should be consid-
ered. The main limitation is inherent to the retrospective
design of the study, based on data extracted from long-
term facilities medical charts not scrupulously filled in.
Moreover, retrospective observationmakes it extremely diffi-
cult to define causality between adverse events and current
hypoglycemic therapy, which however was not among the
main goals of this study. On the other hand, this study in
our view has some strengths that should be highlighted. To
the best of our knowledge this is one of the first attempts
to comprehensively evaluate global health status, including
functional and cognitive conditions, among older patients
with T2DM in long-term facilities. The high number of
patients enrolled from a variegated sample of regional long-
term facilities and the close similarity of our findings with
results from the French study suggest that our results may
reasonably and wisely be generalized to older Southern
Europe patients living in long-term facilities.
In conclusion, our results documented that roughly
three-fourths of older and frail diabetic patients living in
long-term residences have HbA1c values lower than optimal,
suggesting a potential for hypoglycemic harm especially
among patients with severe cognitive impairment. Despite
the current recommendations that strongly advise using
“soft” HbA1c targets and wise and safe glucose-lowering
medical therapies in these vulnerable patients, our findings
seem to suggest an inappropriate and aggressive glucose-
lowering therapeutic approach in most of these frail and
vulnerable elderly residents.
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